Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer
NCT03450330
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
10
Enrollment
INDUSTRY
Sponsor class
Conditions
Nonsmall Cell Lung Cancer
Interventions
DRUG:
AZD4205
Sponsor
Dizal Pharmaceuticals